Canntab Therapeutics Limited
CTABF · OTC
2/28/2023 | 11/30/2022 | 8/31/2022 | 5/31/2022 | |
|---|---|---|---|---|
| Market Cap | $796 | $1,045 | $7,406 | $9,842 |
| - Cash | $17 | $55 | $145 | $691 |
| + Debt | $1,896 | $2,037 | $1,925 | $1,840 |
| Enterprise Value | $2,676 | $3,027 | $9,185 | $10,991 |
| Revenue | -$22 | $18 | $39 | $40 |
| % Growth | -226% | -54.3% | -2.6% | – |
| Gross Profit | -$5 | $0 | $26 | -$54 |
| % Margin | 22.2% | 2.4% | 68.8% | -137.4% |
| EBITDA | -$160 | -$619 | -$115 | -$1,045 |
| % Margin | 720.3% | -3,519.7% | -298.2% | -2,642.8% |
| Net Income | -$413 | -$1,031 | -$468 | -$1,444 |
| % Margin | 1,862.4% | -5,860.7% | -1,214.9% | -3,652.7% |
| EPS Diluted | -0.011 | -0.027 | -0.012 | -0.037 |
| % Growth | 60% | -120.8% | 67.7% | – |
| Operating Cash Flow | -$38 | -$57 | -$527 | -$779 |
| Capital Expenditures | -$3 | -$12 | $0 | -$13 |
| Free Cash Flow | -$40 | -$70 | -$527 | -$792 |